BNGO logo

BNGO

Bionano Genomics, Inc.NASDAQHealthcare
$1.20+0.84%ClosedMarket Cap: $3.9M

As of 2026-04-06

Valuation

View Details

P/E (TTM)

PEG

P/B

0.15

P/S

0.14

EV/EBITDA

-0.33

DCF Value

$-118.81

FCF Yield

-414.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

22.0%

Operating Margin

-116.9%

Net Margin

-92.6%

ROE

-56.2%

ROA

-38.1%

ROIC

-64.6%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 2025$8.0M$-7.9M$-1.46
FY 2025$28.5M$-26.4M$-4.85
Q3 2025$7.4M$-8.5M$-1.59
Q2 2025$6.7M$-6.9M$-1.99

Analyst Ratings

View All
HC Wainwright & Co.Buy
2025-11-24
HC Wainwright & Co.Buy
2025-08-18
Maxim GroupBuy
2025-05-20

Trading Activity

Insider Trades

View All
Chaubey Alkaofficer: CHIEF MEDICAL OFFICER
SellWed Feb 18
Adamchak Markofficer: Principal Accounting Officer
SellWed Feb 18
Dixon Jonathan V.officer: GENERAL COUNSEL
SellWed Feb 18
OLDAKOWSKI MARKofficer: CHIEF OPERATING OFFICER
SellWed Feb 18
Holmlin R. Erikdirector, officer: PRESIDENT AND CEO
SellWed Feb 18

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NASDAQ

Beta

1.60

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Peers